, Hyderabad has developed the technology to){kind=link}
The Indian Institute of Chemical Technology (IICT), Hyderabad has developed the technology to make the drug Favipiravir, which has been proved as an essential drug to treat the deadly COVID-19 infection. Using this, the Raghava life Sciences (RLS) finally succeeded in making this drug all on their own.
Japan is using this Favipiravir drug as the first-line medication to treat its patients and countries like Turkey and China have reported that they have attained excellent results after the administration of this drug to the patients. On the other side, scientists from all over the world are trying their best to bring in a suitable vaccine to treat this virus.
The same Favipiravir has undergone clinical trials in Russia. Total 90 subjects were administered with this drug and the recovery rate has increased from 55.86% to 71.53%. The time period for the recovery from the virus infection is also reduced from 11 days to 4 days. Most impressively, Raghava life Sciences (RLS) developed this drug with the raw material that is available in India and there is no need to look at the foreign counters now.
Favipiravir is used in countries such as China and Japan to treat influenza. Whenever a virus enters a cell, it tries to create multiple replicas. Favipiravir stops the replication process, which is crucial for a virus to multiply its number in a host.